Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : Applied Materials No-Politics Thread (AMAT) -- Ignore unavailable to you. Want to Upgrade?

To: Fred Levine who wrote (5145)	1/23/2003 2:55:52 PM
From: Jacob Snyder	Respond to of 25522

Interesting, but it will never be a mass market. Even when we all have a variety of chips in devices implanted in our bodies, we'll use far more in our toys and cars. The next step (and serious money is going into R&D in this area), is implantable devices to monitor and treat chronic conditions. Diabetics will get realtime continuous blood sugar monitoring (just like a functioning pancreas does). Enzymes that spike during heart attacks will be monitored, and the implanted device will call 911 for you. After those devices are developed, the next step is to connect them with implanted devices to deliver insulin and blood-thinners, at the right dose, when needed.

To: Fred Levine who wrote (5145)	1/23/2003 5:57:07 PM
From: Proud_Infidel	Read Replies (2) \| Respond to of 25522

VSEA forcasting sequential growth of 19%-39%: biz.yahoo.com Halliday also provided forward guidance, noting that, "We currently expect revenue for the second quarter of fiscal 2003 to be between $100 and $115 million, and shipments to range from $95 to $110 million. Gross margin is expected to be in the mid- to high- 30s as a percentage of revenue due to increased pricing pressure in the industry as a result of low customer capital spending. Earnings per share are anticipated to range between $0.10 to $0.20 per share."